72 patients severely immunocompromised by their underlying disease ( marrow aplasia , acute leukaemia , or solid tumour ) or by the treatment they were receiving , or both , were randomised to receive antifungal prophylaxis with either oral ketoconazole or conventional doses of oral amphotericin b and nystatin .
C0003308
antifungal
C0022625
ketoconazole